BridgeBio (NASDAQ: BBIO) CAO withholds 4,714 shares for RSU taxes

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) reported that Chief Accounting Officer Maricel Apuli had 4,714 shares of common stock withheld on 2026-08-16 to satisfy tax obligations related to vesting of 9,262 RSU-based shares. After this tax-withholding disposition, Apuli directly holds 122,687 shares of BridgeBio common stock.

Insider Trade Summary

Net Seller: 4,714 shares

Net Sell 1 txn

Insider Apuli Maricel

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	4,714	$79.86	$376K

Holdings After Transaction: Common Stock — 122,687 shares (Direct)

Footnotes (1)

1. F1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs.

Key Figures

Shares withheld for taxes: 4,714 shares Per-share value for withholding: $79.86 per share Shares underlying vested RSUs: 9,262 shares +2 more

5 metrics

Shares withheld for taxes 4,714 shares Common stock withheld to satisfy tax obligation on 2026-08-16

Per-share value for withholding $79.86 per share Value applied to the 4,714 withheld shares

Shares underlying vested RSUs 9,262 shares Common stock underlying RSUs that vested for the reporting person

Shares held after transaction 122,687 shares Direct holdings of BridgeBio common stock after the withholding

Transactions for tax liability 1 transaction Code F tax-withholding disposition reported in this Form 4

Key Terms

Restricted Stock Units, tax obligation, withheld to satisfy

3 terms

Restricted Stock Units financial

"underlying the Reporting Person's RSUs"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligation financial

"withheld to satisfy the Reporting Person's tax obligation"

withheld to satisfy financial

"shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax"

FAQ

What insider transaction did BBIO report for Maricel Apuli on August 16, 2026?

BridgeBio Pharma (BBIO) reported that Maricel Apuli had 4,714 shares of common stock withheld on 2026-08-16 to pay taxes on RSU vesting. This was a tax-withholding disposition, not an open-market sale.

How many BBIO RSU-related shares vested for Maricel Apuli in this Form 4 filing?

The filing states that 9,262 shares of BridgeBio common stock underlying Maricel Apuli’s RSUs vested. From these vested shares, 4,714 were withheld to satisfy tax obligations, with the remainder delivered to the insider.

What is Maricel Apuli’s BBIO shareholding after the reported tax withholding?

Following the reported transaction, Maricel Apuli directly holds 122,687 shares of BridgeBio common stock. This figure reflects her position after 4,714 shares were withheld to cover tax liabilities associated with RSU vesting.

At what value were the withheld BBIO shares recorded in the Form 4 transaction?

The 4,714 withheld shares were valued at $79.86 per share for the transaction. This per-share value is used solely for reporting the tax-withholding disposition, not as an open-market trade price.

Was the August 16, 2026 BBIO insider transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating the transaction is not affirmed as under a 10b5-1 trading plan. The transaction was for tax withholding tied to RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 06:03 PM Accepted by SEC EDGAR 08/18/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Apuli Maricel

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/16/2026		F		4,714(1)	D	$79.86	122,687	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,262 shares of Common Stock underlying the Reporting Person's RSUs.

Remarks:

	/s/ Maricel Apuli	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)